Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

Read more
CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

Read more
CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Read more
Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Read more
Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Read more
Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

Read more
previous arrow
next arrow
Hits: 689399
TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

Written by Remi Jeandenand on . Posted in News

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn